Shanghai Pharma and Novartis China have inked a deal on several ophthalmic products, they said yesterday. The Swiss drugmaker will tap into Shanghai Pharma’s integrated marketing services to expand its established anti-infection and glaucoma drugs into new, previously untargeted markets.